NYSE$STE

STERIS PLC · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

STERIS's third quarter revenue increased, with solid growth in a challenging environment.

STERIS announced financial results for its fiscal 2022 third quarter ended December 31, 2021. Revenue increased 49% to $1.2 billion compared to the third quarter of fiscal 2021. Constant currency organic revenue increased 9%. As reported, net income for the third quarter was $143.6 million, or $1.42 per diluted share, compared to $114.5 million, or $1.33 per diluted share, in the third quarter of fiscal 2021.

  • Third quarter revenue increased 49% as reported; 9% constant currency organic
  • As reported EPS of $1.42; adjusted EPS of $2.12
  • Healthcare revenue grew 46% to $759.7 million
  • Outlook for FY22 raised

Headline financials

Total Revenue

$1.21B

Previous: $809M+49.5%
EPS (adj)

$2.12

Previous: $1.73+22.5%
Const. Curr. Organic Growth

9.0%

Previous: 1.0%+800.0%
Capital Expenditures

-$214M

Previous: -$164M-30.4%
Free Cash Flow

$299M

Previous: $337M-11.5%
Net Income

$144M

Previous: $115M+25.4%
Operating Income

$203M

Previous: $147M+38.0%
Gross Profit

$538M

Previous: $346M+55.6%
Cash & Equivalents

$359M

Previous: $253M+42.2%
Total Assets

$11.7B

Previous: $6.58B+77.6%
Stock-Based Comp

$10M

Previous: $6.02M+66.0%

Revenue & EPS history

STERIS · Revenue · Quarterly

$1.21B

Q3 2022+49.5%vs Q3 2021
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

STERIS · $1.59B total across 3 segments · Q4 2027

  • Healthcare
    $1.14B
  • Applied Sterilization Technologies
    $289M
  • Life Sciences
    $163M

Forward guidance

The Company is updating its expectations for fiscal 2022. Constant currency organic revenue growth is now anticipated to be approximately 11%. Adjusted earnings per diluted share are now anticipated to be in the range of $7.85 to $7.95.

Tailwinds

  • Constant currency organic revenue growth is now anticipated to be approximately 11%
  • Adjusted earnings per diluted share are now anticipated to be in the range of $7.85 to $7.95
  • The increased outlook reflects solid growth across the business
  • Higher cost synergies from the Cantel acquisition
  • Capital expenditures are now anticipated to be approximately $300 million and free cash flow is expected to be approximately $420 million.

Headwinds

  • Continued challenges from supply chain
  • Inflation
  • Earnings dilution from the recent divestiture of the Renal Care business
  • Supply chain constraints
  • Lower patient volumes

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+0.5%

Avg return

Earnings day

+1.0%

Avg return

5 days after

+1.3%

Avg return

30 days after

59%

38 / 64 earnings

Positive

+12.9%

Q4 2014

Best reaction

-11.4%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2027+0.0%+7.2%+2.8%
Q3 2026-7.7%-7.4%-12.8%
Q2 2026+7.0%+9.7%+8.3%
Q4 2025+8.6%+10.1%+6.1%
Q3 2025+2.1%+1.1%+5.4%
Q2 2025-5.2%-2.5%-5.1%
Q1 2025-1.8%-0.8%+0.5%
Q4 2024+6.2%+9.2%+6.6%
Q3 2024-2.5%-0.4%+3.4%
Q2 2024-5.1%-8.4%-7.1%
Q1 2024+1.0%+0.2%+1.8%
Q4 2023+11.2%+12.7%+10.6%
Q3 2023-11.4%-9.5%-18.2%
Q2 2023+3.5%+2.6%+17.3%
Q1 2023-8.8%-4.7%-10.0%
Q4 2022+1.4%+1.2%+2.6%
Q3 2022+4.6%+1.3%-2.1%
Q2 2022-5.5%-4.8%-6.4%
Q1 2022+0.6%+1.2%+0.2%
Q4 2021-3.6%-3.1%+1.9%
Q3 2021-1.9%-1.7%-8.1%
Q2 2021-0.5%+2.5%+8.8%
Q1 2021-1.0%-3.4%+2.5%
Q4 2020+1.2%+7.0%+1.8%
Q3 2020+6.1%+10.2%-5.0%
Q2 2020+2.3%+2.6%+8.4%
Q1 2020+3.0%+4.1%+3.0%
Q4 2019+1.1%+3.2%+10.2%
Q3 2019+1.9%+3.1%+3.6%
Q2 2019+7.0%+7.4%+5.4%
Q1 2019-0.7%-1.1%-1.9%
Q4 2018+4.7%+4.6%+8.6%
Q3 2018-4.7%-2.8%+7.8%
Q2 2018-6.0%-6.6%-3.9%
Q1 2018+4.9%+3.3%+5.8%
Q4 2017+1.4%-0.4%+6.4%
Q3 2017-6.5%-5.7%-3.4%
Q2 2017-3.0%+0.5%-2.0%
Q1 2017-1.6%-1.9%-2.0%
Q4 2016-0.5%
Q3 2016-1.9%
Q2 2016+6.4%
Q1 2016+0.7%
Q4 2015+2.5%
Q3 2015+1.1%
Q2 2015+3.5%
Q1 2015+0.3%
Q4 2014+12.9%
Q3 2014+0.5%
Q2 2014-3.6%
Q1 2014-3.6%
Q4 2013+8.3%
Q3 2013+1.4%
Q1 2013+1.4%
Q2 2013+1.1%
Q4 2012-0.3%
Q3 2012+0.8%
Q1 2012+0.8%
Q2 2012-4.4%
Q4 2011+0.3%
Q3 2010+0.2%
Q1 2010+0.2%
Q2 2010+0.8%
Q4 2010-0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro